Diaccurate acquires Biokinesis to create a sole-in-class biotech player in oncology and immunotherapy
- BIOKINESIS absorption by DIACCURATE occurred early December 2020
- Dr. Dominique BRIDON leads the new entity
- DIACCURATE is now developing 3 programs in cancer and immunotherapy
- DIACCURATE will be initiating a first clinical trial by early 2022
By acquiring BIOKINESIS, a French biotech that develops the very first anticancer compound targeting the Golgi apparatus, DIACCURATE comforts its “sole-in-class” therapeutic strategy in oncology and immunotherapy. The company is developing a new generation of drug candidates which relies on novel mechanisms of action and untapped cellular and subcellular compartments. Initial data already suggest that this highly innovative approach could help to improve resitance to cancer progression and extend the benefits of immunotherapy to more indications and patients.
“I am delighted to join DIACCURATE the past year and I am extremely impressed by the scientific rationale and the high level of expertise of the company. This acquisition offers us the opportunity to lead an exciting “sole-in-class” approach in a new entity with an international outlook and a very ambitious development strategy. Thus, DIACCURATE should rapidly extend its portfolio by in licensing a drug-candidate with high therapeutic potential in oncology” explained Dr. Dominique BRIDON, CEO of DIACCURATE.
“I am convinced the synergies resulting from this merger will ultimately help to take up the main current challenge of oncology and immunotherapy: broaden the efficacy of checkpoints inhibitors and therapeutics vaccines by restoring a functionnal immune system. That is why TRUFFLE CAPITAL, leading investor of the two companies has been driver in creating a new entity with a strong and differentiated value proposition.” stated Dr. Philippe POULETTY, Co-founder and Chairman of DIACCURATE, Co-founder and CEO of TRUFFLE CAPITAL.
“The BIOKINESIS acquisition will give the means to accelerate the development of the KIF20A inhibitor DIACC2010, the very first Golgi-targeted drug candidate. This perspective is exciting given the impressive preclinical data shown in Acute Myeloid Leukemia and Lymphoma. I am very happy to join the DIACCURATE team as VP Operations” said Cécile BOUGERET, former CEO & CSO of BIOKINESIS, now VP Operations at DIACCURATE.